Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 4/20 | 0.70 |
| ▸ | CPA3 | P15088 | 3/20 | 0.70 |
| ▸ | CPB1 | P15086 | 1/20 | 0.70 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9848631 | 0.88 | CYP1A2 (0.65) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL7410516 | 0.87 | CPA1 (0.68) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL7354310 | 0.86 | CPA3 (0.66) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL2398335 | 0.86 | CPA1 (0.66) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL8399603 | 0.86 | CPA3 (0.66) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL7289839 | 0.86 | CPA3 (0.66) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL1914987 | 0.86 | CPA1 (0.66) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL901408 | 0.86 | CPA1 (0.66) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL9226958 | 0.84 | CPA3 (0.64) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL8106533 | 0.83 | CYP1A2 (0.59) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045414-B2 | Pyrrolidin-2-ones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| EP-2346852-B1 | PYRROLIDIN-2-ONES AS HDM2 LIGANDS | BOEHRINGER INGELHEIM INT (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20120122839-A1 | NOVEL PYRROLIDIN-2-ONES | PRIAXON AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-8119623-B2 | Pyrrolidin-2-ones | PRIAXON AG (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2346852-A1 | PYRROLIDIN-2-ONES AS HDM2 LIGANDS | Priaxon AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100075949-A1 | NOVEL PYRROLIDIN-2-ONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| WO-2010028862-A1 | PYRROLIDIN-2-ONES AS HDM2 LIGANDS | PRIAXON AG (DE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075949-A1 | NOVEL PYRROLIDIN-2-ONES | ING2, HMGB2, API5 | CPA1 3289/4885CPA3 4357/4885CPB1 1749/4885 |
| US-20120122839-A1 | NOVEL PYRROLIDIN-2-ONES | ING2, HMGB2, API5 | CPA1 3289/4885CPA3 4357/4885CPB1 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.